Tritace (ramipril) tablets 5 mg. №28

Description

Tritace (ramipril) tablets 5 mg. №28

Composition

active ingredient: ramipril;

• 1 tablet 5 mg contains ramipril 5 mg;
  excipients: hypromelose, pregelatinized starch, microcrystalline cellulose, iron oxide red (E 172), sodium stearyl fumarate;
• 1 tablet 10 mg contains 10 mg ramipril;
  excipients: hypromelose, pregelatinized starch, microcrystalline cellulose, sodium stearyl fumarate.

Dosage form

Tablets.

Basic physical and chemical properties:

• 5 mg tablets: pale pink oblong tablets with a distribution line on both sides; top stamp: 5 and company logo*, bottom stamp: 5 and HMP* (stamping order may vary);
• 10 mg tablets: white or almost white oblong tablets with a distribution line on both sides; top stamp: NMO/NMO.

Pharmacological group

Angiotensin-converting enzyme (ACE) inhibitors. ACE inhibitors are monocomponent. Ramipril.
ATX code C09A A05.

Pharmacological properties

It is a blood pressure lowering (antihypertensive) medicine. Ramipril breaks down in the liver to form ramiprilat. It acts by inhibiting the renin-angiotensin-aldosterone system. Suppresses the effect of the angiotensin-converting enzyme, which catalyzes the conversion of angiotensin-I into the vasoconstrictor peptide angiotensin-II, while preventing its stimulating effect on the process of aldosterone secretion by the adrenal glands.

Indications

Tritace tablets applies:

• for the treatment of hypertension (arterial hypertension);
• for the prevention of cardiovascular complications and mortality in patients with severe atherothrombotic changes;
• with diabetes mellitus with at least one risk factor for the development of cardiovascular complications;
• for the treatment of kidney disease (glomerular diabetic nephropathy with at least one risk factor for the development of cardiovascular complications;
• with heart failure with clinical manifestations;
• for secondary prevention after acute myocardial infarction: to reduce mortality during the acute phase of myocardial infarction in patients with clinical manifestation of heart failure.

Contraindications

Do not use Tritace tablets:

• with intolerance to the components;
• with intolerance to other ACE inhibitors;
• with a history of angioedema;
• with stenosis of the renal artery (a. renalis) of the only kidney or bilateral stenosis of the renal artery (aa. renalis dextra et sinistra);
• during extracorporeal treatment, which is accompanied by blood contact with negatively charged surfaces;
• with unstable hemodynamics;
• with arterial hypotension;
• during pregnancy / lactation, planning pregnancy.

Application during pregnancy and lactation

This medicine is contraindicated in pregnant women, as well as in women planning pregnancy. Not applicable to nursing mothers.

Method of administration and dosage

Tritace is used internally.
The standard initial dose is 1.25–2.5 mg, the therapeutic dose is 5–10 mg, and the maximum is 10 mg.
The prescribed dose should be taken once a day, every day at the same time, regardless of food.

Overdose

Symptoms: vascular insufficiency, renal failure, drop in blood pressure, electrolyte imbalance, anxiety, tachycardia / bradycardia, hyperventilation, palpitations, dizziness, cough.
It is necessary to take measures to remove the drug from the body (artificially induce vomiting or rinse the stomach, apply sorbents, sodium sulfate). In case of an overdose, the introduction of saline, angiotensin II, catecholamines is recommended.

Side effects:

• Cardiac disorders: myocardial ischemia, including angina pectoris or myocardial infarction, tachycardia, arrhythmia;
• Disorders from the blood and lymphatic system: eosinophilia;
• Disorders from the nervous system: headache, dizziness, vertigo, paresthesia, ageusia, dysgeusia;
• On the part of the organs of vision: visual disturbances, including blurred vision;
• Respiratory, thoracic and mediastinal disorders: unproductive irritating cough, bronchitis, sinusitis, shortness of breath, bronchospasm, including exacerbation of asthma, nasal congestion;
• Disorders from the gastrointestinal tract: inflammation in the gastrointestinal tract, digestive disorders, abdominal discomfort, dyspepsia, diarrhea, nausea, vomiting, pancreatitis;
• Disorders from the kidneys and urinary tract: impaired renal function;
• Disorders from the skin and subcutaneous tissues: rashes, in particular maculo-papular, angioedema;
• Disorders of the musculoskeletal system and connective tissue: muscle spasms, myalgia, arthralgia;
• Metabolic and nutritional disorders: increased levels of potassium in the blood, anorexia, loss of appetite;
• Vascular disorders: arterial hypotension, orthostatic decrease in blood pressure, syncope, sensation of hot flashes.